Anti-hepatitis push raises ethical issues.
Jaklevic
M C
MC
D002487:Centers for Disease Control and Prevention, U.S.; D002985:Clinical Protocols; D003299:Cooperative Behavior; D019468:Disease Management; D004345:Drug Industry / Q000592:standards; D004992:Ethics, Medical; D005845:Georgia; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000191:economics; D006801:Humans; D007193:Independent Practice Associations / Q000592:standards*; D007370:Interferon Type I / Q000627:therapeutic use; D011994:Recombinant Proteins; D014481:United States; D014486:United States Food and Drug Administration
D007370:Interferon Type I; D011994:Recombinant Proteins